에 대한 최신 뉴스 Centene (NYSE:CNC) 주식

Centene

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.

Large Cap

News

Short Sellers

Movers

Trading Ideas

ASML

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ERIE

KLAC

LRCX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 니오(NYSE:NIO)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 중국의 9월 수출이 예상치를 밑돌면서 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.

니오, ASML 및 CVS 헬스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 14일-18일)

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Conduit Capital Ltd

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

CHINA TELETECH HLDGS INC by China Teletech Holding, Inc.

China Teletech Holding Inc

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) stock lost 16.35% last week as U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">fell after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) stock dipped 15.58%, probably due to continued weakness following weak guidance from ASML.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares were down 14.38%. The company will report <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">third-quarter results on October 25</a>.</li>
<li>Elevance Health shares dipped 14.17% after analysts cut forecasts <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">following third-quarter earnings</a>.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares tumbled 13.97% after the company accidentally released earnings a day ahead of schedule and <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">cut its 2025 sales forecast</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) stock fell 13.91%, as did U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were down 12.24%, probably in sympathy with Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), which reported third-quarter earnings miss and issued soft FY24 guidance.</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) stock dived 12.12%, probably in sympathy with Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), which reported better-than-expected <a href="https://www.benzinga.com//node/41377745" target="_blank" rel="noreferrer noopener">earnings and issued strong guidance</a>.</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) fell 9.92% last week after Spruce Point Management <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">issued a short-sell report</a> on the stock. The company was under pressure due to Category 5 Hurricane Milton.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) stock fell 9.44% last week after the company <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">cut its Q3 outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41418879/coinbase-united-airlines-and-sofi-tech-are-among-top-11-large-cap-gainers-last-week-oct-14-18-are-" target="_blank" rel="noreferrer noopener">Coinbase, United Airlines And Sofi Tech Are Among Top 11 Large Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?

Deep-pocketed investors have adopted a bearish approach towards Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CNC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Centene. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 19% leaning bullish and 76% bearish. Among these notable options, 15 are puts, totaling $4,405,390, and 6 are calls, amounting to $307,439.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $67.5 for Centene during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Centene's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Centene's whale trades within a strike price range from $55.0 to $67.5 in the last 30 days. 
<h3>Centene 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729197113_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.3</td>
<td>$66.00</td>
<td>$1.6M</td>
<td>11.9K</td>
<td>8.9K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$1.1</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$55.00</td>
<td>$730.0K</td>
<td>0</td>
<td>7.6K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$66.00</td>
<td>$330.1K</td>
<td>11.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.2</td>
<td>$2.5</td>
<td>$3.0</td>
<td>$66.00</td>
<td>$300.0K</td>
<td>11.9K</td>
<td>11.9K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.4</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$66.00</td>
<td>$273.6K</td>
<td>11.9K</td>
<td>3.0K</td>
</tr>
</tbody>
</table>

<h3>About Centene</h3>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Having examined the options trading patterns of Centene, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Centene Standing Right Now?</h3>
<ul>
<li>With a volume of 14,571,018, the price of CNC is down -8.8% at $63.2. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Centene</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $90.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $90. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Centene with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Centene Options Trading: A Deep Dive into Market Sentiment

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has fallen 18.84% since its last report. The company recently reported that it has 7.80 million shares sold short, which is 1.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729179912_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Ideas

Looking Into Centene's Recent Short Interest

WIIM

Shares of health insurance stocks are trading lower in sympathy with Elevance Health, which reported a Q3 earnings miss and issued soft FY24 guidance.

Shares of health insurers are trading lower in sympathy with UnitedHealth, which reported Q3 financial results and lowered the upper end range of annual EPS outlook.

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4277602-1&amp;h=4074998618&amp;u=https%3A%2F%2Fwww.centene.com%2F&amp;a=Centene+Corporation">Centene Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4277602-1&amp;h=607808981&amp;u=https%3A%2F%2Fwww.mimeridian.com%2F&amp;a=Meridian+Health+Plan+of+Michigan%2C+Inc.">Meridian Health Plan of Michigan, Inc.</a>&nbsp;("Meridian"), has been selected by the Michigan Department of Health and Human Services (MDHHS) to provide highly integrated Medicare and Medicaid services for dually eligible Michiganders through a Highly Integrated Dual Eligible Special Needs Plan (HIDE SNP). The plan will launch on Jan. 1, 2026, when Michigan's MI Health Link pilot program transitions from a Medicare-Medicaid Plan (MMP) to MI Coordinated Health, a HIDE SNP in coordination with the Centers for Medicare and Medicaid Services (CMS).

Contracts

Centene's Meridian Health Plan Of Michigan Awarded Contract To Serve Dual Eligibile Medicare And Medicaid Members In Michigan

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 5.29% on an annualized basis producing an average annual return of 13.91%. Currently, Centene has a market capitalization of $38.08 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 20 years ago, it would be worth $1,305.23 today based on a price of $72.39 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728680441_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Centene 20 Years Ago Would Be Worth Today

This represents meaningful progress and is consistent with internal expectations despite higher than industry-anticipated cut point changes. Additionally, it is appealing TTY results with CMS.
The Centers for Medicare and Medicaid Services (CMS) issued 2025 Medicare Advantage Star Ratings on October 10, 2024.&nbsp;

Centene Has Approximately 46% Of Its Medicare Advantage Membership Enrolled In Plans Rated 3.5 Stars Or Higher Vs. Approximately 23% Prior Year - Filing

CLOV

EHTH

ELEV

GOCO

Biden-Harris Administration Proposes Medicare $2 Drug List Model To Lower Prescription Costs; CMS Seeks Feedback On Sample Drug List And Outreach With Voluntary Participation For Part D Sponsors Starting As Early As Jan 2027; Model To Include Drugs For Common Conditions With Periodic Updates Based On New Generics, Clinical Indications, And Pricing Trends

Shares of&nbsp;Humana Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) have dropped 30.2% over the past month to close at $240.03 on Friday. The steep declines last week have pushed the stock&#39;s price closer to the lower end of its 52-week range of $213.31-$530.54. Having underperformed its peers like&nbsp;Molina Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) and Centene Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnc#NYSE">CNC</a>), the overall industry, and the S&amp;P 500, the company&#39;s current share price seems an excellent opportunity to build a position in a renowned HMO company. After all, you would much rather buy closer to the low than the high, right?&nbsp;
<h2>One-Month Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e4/80609.jpg?v=334232142" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
HUM is trading below its 50 and 200-day moving averages, indicating a bearish outlook. Buying closer to the low can be attractive, but context matters - let&#39;s explore further.
<h2>HUM&#39;s Falling Stars</h2>
HUM experienced its worst share price fall since the financial crisis due to losing high-quality ratings on its major Medicare Advantage plans, which generate substantial revenue. The news slashed its star-rated membership from 94% to around 25%, triggering a selloff that wiped out a massive chunk of its market value.
This has not only affected Humana but also rippled through the broader health insurance sector. The health insurer, like many others, is already facing growing medical costs and tighter reimbursements from the government. This latest development is bound to affect its profit levels.
<h2>Analysts Downgrade HUM&#39;s Earnings Estimates</h2>
Reflecting the negative sentiment around Humana, the Zacks Consensus Estimate for earnings per share has seen downward revisions. The consensus estimate for 2024 adjusted earnings for HUM is currently pegged at $16.12 per share, indicating a 38.2% year-over-year decline. Over the past four quarters, its average earnings surprise is at negative 2.5%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9b/80608.jpg?v=386647277" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>HUM&#39;s Headwinds</h2>
With a sharp decline expected in Humana&#39;s top-rated Medicare Advantage plan enrollments next year, its revenues are likely to take a hit. This drop is expected to ripple through its partner network, affecting them depending on payment structures. The company has already been dealing with an anticipated membership decline, and this new development further hinders its member growth strategies.
In addition, Humana has been grappling with rising operating expenses. Over the past few years, operating costs surged 10.7% in 2021, 11.5% in 2022, and 14.9% in 2023. The trend has continued, with a 12.8% increase in operating expenses reported in the first half of 2024. The rise is attributed to higher benefits and operating costs, which are likely to pressure profit margins moving forward. Moreover, as senior citizens continue to resume elective procedures post-pandemic, medical costs are set to escalate further, adding to the company&#39;s financial challenges.
Also, its rising debt level is a concern. Long-term debt amounted to $11.7 billion at second-quarter end, up 15% from the figure as of Dec. 31, 2023.&nbsp;Its long-term debt to capital of 41.25% is higher than the industry average of 38.26%.
<h2>Final Words: Steer Clear of HUM Stocks</h2>
Humana is facing significant challenges, including membership decline, rising costs and debt burden. The stock is trading below key moving averages, signaling a bearish trend. With analysts downgrading earnings estimates, investors should approach HUM stock with caution as it shows serious downside potential. It currently carries a Zacks Rank #4 (Sell).
<a href="https://www.zacks.com/stock/news/2347052/humana-stock-getting-closer-to-52-week-lows-a-buying-opportunity?cid=CS-BENZ-FT-analyst_blog|52week_high/low-2347052">To read this article on Zacks.com click here.</a>

Earnings

Health Care

Analyst Ratings

General

Humana Stock Getting Closer to 52-Week Lows: A Buying Opportunity?

Cantor Fitzgerald analyst Sarah James reiterates Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and maintains $90 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Centene, Maintains $90 Price Target

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has fallen 5.05% since its last report. The company recently reported that it has 9.62 million shares sold short, which is 2.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727714722_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Centene's Health Net Subsidiary Selected For California Medicaid Dental Contract In Los Angeles And Sacramento Counties, Starting July 2025

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 20 years by 5.58% on an annualized basis producing an average annual return of 14.06%. Currently, Centene has a market capitalization of $39.78 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 20 years ago, it would be worth $1,562.27 today based on a price of $75.63 for CNC at the time of writing.
<h3>Centene's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726860634_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth $1,600 Today

Guidance

Centene Expects To Reaffirm 2024 Adjusted EPS Guidance Of Greater Than $6.80 (Est $6.82) At Investors Meet On Sept. 17, 2024 And Bank Of America 2024 Global Healthcare Conference - Filing

Wells Fargo analyst Stephen Baxter maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $93 to $91.

Wells Fargo Maintains Overweight on Centene, Lowers Price Target to $91

Consistent with the Company&rsquo;s guidance previously provided on September 4, 2024, the senior management team plans to:
&bull;reiterate the shift of 20 to 30 cents of adjusted diluted EPS from Q3 to Q4. Therefore, the Company projects Q3 adjusted diluted EPS of between $1.31 to $1.41, with the remainder of the 2024 full year adjusted diluted EPS to be realized in Q4; and
&bull;reiterate that, with regard to Medicare Advantage, the Company continues to be encouraged by the progress it has made in the improvement of its stars program performance.

Centene Plans To Reaffirm 2024 Adjusted EPS Guidance Of Greater Than $6.80 (Est $6.83); Reiterate Shift Of 20 To 30 Cents Of Adjusted EPS From Q3 To Q4, With Q3 Adjusted EPS At $1.31 - $1.41 (Est $1.51) - Filing

In the preceding three months, 17 analysts have released ratings for Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Centene, presenting an average target of $88.18, a high estimate of $110.00, and a low estimate of $69.00. Observing a downward trend, the current average is 2.22% lower than the prior average price target of $90.18. 
<img src="https://www.benzinga.com/files/images/story/2024/1725552042_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Centene among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$69.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Calvin Sternick</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Centene. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Centene's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Centene's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Centene analyst ratings.</a>
<h2>Get to Know Centene Better</h2>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
<h3>Financial Milestones: Centene's Journey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 5.92%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 2.88%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Centene's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Centene's ROA stands out, surpassing industry averages. With an impressive ROA of 1.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Centene's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.64, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Centene Stock: A Deep Dive Into Analyst Perspectives (17 Ratings)

Most major U.S. managed care insurers set for sequential earnings declines in Q3

UnitedHealth dips as cost concerns weigh on insurance unit

UnitedHealth in selloff as 2025 outlook disappoints

UnitedHealth drags rivals as 2025 outlook disappoints

Elevance Health stock slides after outlook cut amid rising medical expenses

ONEV: Not Really A Low-Volatility ETF

Molina, Centene see big drops following Elevance Health profit warning

Catalyst Watch: Earnings blitz, Fed speakers, and notable healthcare conferences

Wall Street Breakfast: What Moved Markets

Three events that shook health insurers this week

ACGL

ACGLN

ACGLO

ALHC

ALTM

ANRO

ASAN

AXNX

BIOX

BMYMP

BYON

CALM

CAMRF

CTSH

DENN

ETON

FDLO

FFIE

GILD

LGLV

LOGI

MEDP

MNDY

NFLX

ONEV

ORLY

OSCR

QCOM

RIVN

SPLV

TEAM

TMUS

TSLA

UBER

USMV

WHLR

Press Releases

Ambetter from Nebraska Total Care Offers Health Insurance Statewide in Nebraska in 2025

Ambetter from Superior HealthPlan Offers Health Insurance in 149 Counties Across Texas in 2025

Ambetter from Health Net Offers Health Insurance to 10 Counties Across California in 2025

Ambetter Health Expands Geographic Footprint and Enhances Member Benefits in 2025

Astrana Health Completes Acquisition of Collaborative Health Systems

CENTENE CORPORATION TO HOST 2024 THIRD QUARTER FINANCIAL RESULTS EARNINGS CALL

CENTENE SUBSIDIARY MERIDIAN IN MICHIGAN AWARDED CONTRACT TO SERVE DUAL ELIGIBILE MEDICARE AND MEDICAID MEMBERS IN MICHIGAN

Peach State Health Plan and Centene Foundation Announce $100,000 Donation to Support Hurricane Relief Efforts in Georgia

OKLAHOMA COMPLETE HEALTH DONATES $75,000 TO THE FOSTER CARE ASSOCIATION OF OKLAHOMA TO SUPPORT FOSTER FAMILIES

Health Net Only Health Plan in United States to Receive "Health Equity Accreditation Plus" Across All Lines of Business for 2024

ASTH

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Elevance Health

HealthEquity

Humana

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

Cantor Fitzgerald

Wells Fargo

Barclays

Stephens & Co.

Deutsche Bank

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)의 주식이 지난주 16.35% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 후 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
2. KLA 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>)의 주식이 지난주 15.58% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
3. 센텐 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>)의 주식이 14.38% 하락했다. 이 회사는 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">10월 25일 3분기 실적을 발표</a>할 예정이다.
4. 엘레반스 헬스(Elevance Health)의 주식이 14.17% 하락했다. 이는 분석가들이 <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">3분기 실적 발표 후 전망을 하향 조정한</a> 데 따른 것이다.
5. ASML 홀딩 N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)의 주식이 13.97% 하락했다. 회사가 실적 발표를 하루 일찍 실수로 공개하고 <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">2025년 매출 전망을 하향 조정한</a> 후 발생한 일이다.
6. PDD 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)의 주식이 13.91% 하락했다. 이는 미국에 상장된 중국 주식들이 <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">중국의 9월 수출이 예상치를 밑돌면서</a> 하락한 것과 함께 발생한 일이다. 중국 경기 부양책에 대한 불확실성도 최근 주식에 악영향을 미쳤다.
7. 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주식이 12.24% 하락했다. 이는 엘레반스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)와 동반 하락한 것으로 보인다. 엘레반스 헬스는 3분기 실적 부진과 2024년 전망을 낮춰 발표했다.
8. 램 리서치(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>)의 주식이 12.12% 하락했다. 이는 ASML의 부진한 전망 발표 이후 지속적인 약세로 인한 것으로 보인다.
9. 이리 인뎀니티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>)의 주식이 지난주 9.92% 하락했다. 이는 스프루스 포인트 매니지먼트(Spruce Point Management)가 주식에 대한 <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">공매도 보고서를 발표</a>한 후 발생한 일이다. 이 회사는 카테고리 5 허리케인 밀턴으로 압박을 받았다.
10. CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)의 주식이 지난 주 9.44% 하락했다. 이 회사가 <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">3분기 전망을 하향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EC%99%80-%EC%9C%A0%EB%82%98%EC%9D%B4%ED%8B%B0%EB%93%9C-%ED%95%AD%EA%B3%B5%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">코인베이스, 유나이티드 항공 및 소파이 테크가 지난 주 가장 큰 대형주 상승 종목 중 하나 (10월 14-18일): 다른 종목들은 여러분의 포트폴리오에 포함되어 있나요?</a></li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Centene

뉴스

에 대한 최신 뉴스 Centene (NYSE:CNC) 주식

일요일, 10월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌